Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators Announcement Behind the Breakthrough: An Interview with Carl June, the Father of CAR T-Cell Therapy Announcement PICI Network Investigators to Showcase Immunotherapy Advances at ASCO 2024 Announcement Unlocking Complex Cell-based Gene Therapies: A Joint Workshop Hosted by PICI and FOCR Announcement PICI Hosts 2024 Spring Scientific Retreat
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators